Forest And Mylan Confident Nebivolol Will Reach Market In Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA “approvable” letter seen by firms as minor hurdle for previously delayed hypertension drug.
You may also be interested in...
Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market
Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.
Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market
Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.
Forest/Mylan Respond To FDA “Approvable” Letter On Nebivolol
Forest estimates review of the novel hypertension drug could take six months.